12 results about "Vaccine antigen" patented technology

The application provides a buffer for improving the stability of foot-and-mouth disease vaccine antigen, which contains milk serum, sodium chloride, sorbitol, glycine, K2HPO4.3H2O and KH2PO4. The buffer has the effects of improving the thermal stability of 146S antigen and obviously inhibiting the degradation of 146S antigen under the conditions of 4 DEG C and 37 DEG C. The antigen resuspended by the buffer and the prepared vaccine can be stored for a long time under the condition of 4 DEG C. In addition, the buffer is easy to prepare and dissolve, can be used as a medium for resuspending FMD antigen, is a good thermal stability protective agent for FMD antigen and vaccine, can be used in large-scale production, has strong practicability, can obviously reduce the degradation rate of effective antigen in foot-and-mouth disease vaccine under storage conditions and extreme conditions, and obviously improves the product quality.

This invention relates to a homogeneous photocatalytic chemiluminescence detection system for detecting HPV vaccine antigen content, its preparation method, and its application. The system utilizes self-made carboxyl-modified donor microspheres and receptor microspheres, coupled with HPV type-specific monoclonal antibodies via EDC / NHS activation, achieving one-step homogeneous detection. By optimizing the microsphere size, a 200 nm microsphere system was found to exhibit higher luminescence signal, a wider detection range, and better sensitivity when detecting HPV16 / 18 VLPs. This method is simple to operate, requires no plate washing, and possesses good specificity, accuracy, and precision. It is suitable for the in vitro relative potency and identification detection of bivalent HPV vaccines, and can replace traditional ELISA methods, reducing detection costs and safety risks. It is also suitable for large-scale applications in vaccine quality control.

In the present invention, cyclic dinucleotides or their compositions are used as biological response modifiers to enhance the immune response of subjects with deficient immune systems, with a low or absent response to vaccine antigens, or with a deficient immune response to pathogens. The formulations of the present invention are capable of modifying the biological response in such a way as to eliminate the lack of response, resulting in the development of a high-avid immune response that prevents disease caused by infectious agents, particularly viruses with the ability to evade immune surveillance mechanisms and, consequently, suppress the induction of an effective, high-avid adaptive response.The present invention also comprises cyclic dinucleotide formulations, which can be administered alone, in combination with other biological response modifiers, or in vaccine formulations with antigens. The proposed invention further includes a method for preventing or treating acute respiratory infections, preventing disease severity, and blocking transmission by inducing an immune response at the point of entry (nasopharyngeal mucosa), preventing or reducing person-to-person transmission of pathogens / viruses in preventive vaccine formulations, as well as in formulations used for prophylaxis before and after exposure to acute respiratory infections.

This invention discloses a targeted adjuvant influenza vaccine composition for atrial fibrillation patients with atrial fibrosis. The vaccine antigen components are selected from the surface antigens of currently prevalent influenza virus strains, such as hemagglutinin (HA) and neuraminidase (NA). High-purity influenza virus antigens are prepared through cell culture or recombinant DNA technology. For example, influenza virus is cultured using Madin-Darby canine kidney (MDCK) cells, and purified through centrifugation, filtration, and chromatography to obtain high-purity HA and NA antigens. After injection into the human body, the influenza virus antigens (HA and NA) are taken up and processed by antigen-presenting cells (such as macrophages and dendritic cells). The antigen-presenting cells present antigen peptides to T lymphocytes and B lymphocytes, activating a specific immune response. B lymphocytes differentiate into plasma cells with the help of T lymphocytes, producing specific antibodies that recognize and bind to the influenza virus, preventing it from infecting host cells and thus preventing influenza virus infection.

This invention discloses a porcine circovirus vaccine filling device, relating to the field of vaccine filling technology. The device includes a filling assembly comprising a base, a support frame on top of the base, the support frame being L-shaped, a servo motor at the top of the support frame, and a connecting frame fixedly mounted on the bottom telescopic end of the servo motor through the support frame. The connecting frame has several sets of mounting holes arranged sequentially, through which connecting pipes are installed. This invention, by setting up the filling assembly, can effectively buffer the filling process. The sieve plate provides effective buffering and defoaming, solving the problem of air bubbles easily generated during filling in existing devices. It avoids the problem of large differences in drug dosage due to air bubbles, ensuring the product complies with veterinary pharmacopoeia regulations. Simultaneously, it prevents oxygen in the air bubbles from accelerating the oxidative denaturation of vaccine antigen proteins, ensuring the drug's efficacy and preventing immunization failure.

The present application relates to a kind of nucleotide, vaccine comprising it and composite vaccine adjuvant.The sequence of the nucleotide is shown as SEQ ID No:1.Relative to conventional technology, the beneficial effects of the present application include: the present application adopts new optimized sequence, provides a kind of nucleotide, the nucleotide can be as CpG oligonucleotide adjuvant, induces vaccine antigen to produce stronger humoral immunity, cellular immunity level and anti-tumor immune effect etc., has obvious clinical application value and vaccine development value.Moreover, using the immunoadjuvant of the present application helps to reduce the dose of clinical use vaccine, improves safety.

In the case of microstructures that are observable with an electron microscope, such as vaccine antigen particles, there is a challenge in evaluating their hardness, such as whether they are "hard" or "soft," because their scale is so small. This invention has been made in view of these circumstances and provides a method for evaluating the hardness of microstructures in a relatively simple manner. [Solution] A fixed sample was prepared by immobilizing a predetermined microstructure according to a conventional method, and an unfixed sample was prepared without immobilization treatment. The difference in shape due to the effect of surface tension was observed using a transmission electron microscope, and the greater the degree of structural collapse of the microstructure in the unfixed sample compared to the fixed sample, the softer the microstructure was evaluated to solve the problem.

The present invention relates to viral vectors co-encoding an artificial CD4 T cell epitope (PADRE) for enhanced immune responses to encoded multimeric protein particle displayed vaccine antigens.

A hybrid protein comprises a first domain comprising a sequence encoding a surface protein of an enveloped RNA virus and a second domain comprising a sequence encoding an ectodomain of a type 2 transmembrane domain protein, wherein the second domain is located at the C-terminal of the first domain. The hybrid protein or an mRNA encoding such protein can be used as a vaccine against the infection of the enveloped RNA virus.

The application belongs to the technical field of biotechnology, and discloses a vaccine adjuvant containing LLOMe, a vaccine composition and application thereof. The application uses LLOMe as a vaccine adjuvant, which can enhance the activity of dendritic cells (DCs) when used in combination with a vaccine, promote the promotion of vaccine antigens, and improve the prevention and treatment effect of the vaccine. The application first discloses the technical content of LLOMe as a vaccine adjuvant, and the vaccine obtained by combining LLOMe with antigens can significantly enhance the anti-tumor cell immunity, thereby obtaining effective immune activity and treatment effect.

The application belongs to the technical field of biological detection, and particularly relates to a novel coronavirus nanoparticle recombinant protein vaccine antigen content detection method and application thereof. In order to solve the problems of qualitative and quantitative determination of novel coronavirus nanoparticle vaccine antigens, in-vitro titer evaluation and adjuvant adsorption efficiency determination, the application establishes a new detection method. According to the physical characteristics of protein nanoparticle macromolecules, two antibodies are set for different proteins of VLP nanoparticles, i.e. a rabbit anti Anti-HPF antibody designed for VLP ferritin inner core and a HRP-labeled rabbit anti Anti-RBD antibody recognizing the VLP surface coupled RBD antigen, so as to accurately detect the antigen content of the nanoparticle recombinant protein vaccine. The detection method has the advantages of convenient operation, low cost, low laboratory requirement, high safety, etc. The method can be implemented in ordinary laboratories and has a good application prospect.